REACT

The Future of Single Chamber ICDs: BIOTRONIK Takes Unprecedented Market Stance with Proprietary DX Technology

Retrieved on: 
Monday, February 12, 2024
DX, Page, Journal of Cardiovascular Electrophysiology, ESC, Risk, Atrial fibrillation, ICD, PMID, American College, REACT, Patient, EACTS, Task force, Molina Healthcare, Guideline, Diagnosis, Update, MATRIX, Medical device

"We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.

Key Points: 
  • "We are very proud that our DX technology provides the only lead available on the market offering both ventricular pacing/defibrillation and atrial monitoring," said Ryan Walters, BIOTRONIK US President.
  • "Due to DX´s ability to provide additional patient and clinical benefits, it became clear to us that we should be using DX technology with every BIOTRONIK single-chamber ICD."
  • Subclinical atrial fibrillation detection with a floating atrial sensing dipole in single lead implantable cardioverter-defibrillator systems: Results of the SENSE trial.
  • REACT DX registry: Real world REACTion to atrial high rate episodes detected in implantable cardioverter-defibrillator recipients with a DX lead.

Konica Minolta Wins CyberSecured Award from Security Today Magazine

Retrieved on: 
Wednesday, January 31, 2024
Senior, AI, Weapon, REACT, Security, Safety, K-12, CCTV, Emerging technologies, VSS, School, Konica Minolta, Algorithm, Software, Organization, Mobile phone

Ramsey, NJ, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc .

Key Points: 
  • Ramsey, NJ, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc .
  • (Konica Minolta) today announced it received Security Today’s 2023 CyberSecured award for AI Gun Detection for its REACT – Visible Weapon Detection solution.
  • Security Today is a leading industry brand of 1105 Media’s Infrastructure Solutions Group.
  • This AI solution can be a key part of a comprehensive video security strategy for schools and other organizations,” said Vijay Raghavan, Senior Vice President, Strategy and Emerging Technologies, Konica Minolta.

ProKidney Reports Third Quarter Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Webcast, Research, D, International, Biostatistics, Patient, Clinical trial, CKD, Conference, REACT, Pharmaceutical industry, Cryptocurrency

WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2023.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.
  • Following the completion of the presentation, a replay of the webcast will also be accessible on the investor relations section of ProKidney website here .
  • Shares outstanding: Class A and Class B ordinary shares outstanding at September 30, 2023 totaled 235,434,630.

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Retrieved on: 
Monday, November 13, 2023
Chronic kidney disease, Webcast, QP, Renal replacement therapy, GMP, Specialization, International, Physician, Kidney failure, Kidney disease, CVS Health, Risk, Surgeon, Glomerular filtration rate, Data, Patient, Framingham Heart Study, Dialysis, CKD, Boston University, Internal medicine, Baxter International, Albuminuria, Documentation, Health, Nephrology, Business administration, Conference, REACT, Trial of the century, EGFR, Quality of life, Memorial University of Newfoundland, Kellogg School of Management, Commercialization, Medical device, Pharmaceutical industry, Cryptocurrency

Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.

Key Points: 
  • Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.
  • Updated interim REACT RMCL-002 study data support continued investigation of REACT’s potential to benefit patients with moderate and high-risk diabetic CKD.
  • The ongoing Phase 2 clinical study assessed adverse events and changes in kidney function as measured by estimated glomerular filtration rate (eGFR), as primary study endpoints.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.

CACI Awarded $420 Million C5ISR Task Order to Support the U.S. Army

Retrieved on: 
Tuesday, December 12, 2023
Hardware, Other Defense, Contracts, Security, Aerospace, Data Management, Manufacturing, Government Technology, Technology, Defense, Military, Other Technology, Other Manufacturing, Software, Networks, NYSE, CACI, Communication, Computer, IDIQ, System integration, RS3, Analysis, REACT, Engineering, Control, Cyber, ESI, Command, Intelligence

CACI International Inc ( NYSE: CACI ) announced today that it was awarded a five-year, single-award, task order valued at up to $420 million to support the U.S. Army Combat Capabilities Development Command (DEVCOM), Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance & Reconnaissance (C5ISR) Center, and the Engineering and Systems Integration (ESI) Directorate.

Key Points: 
  • CACI International Inc ( NYSE: CACI ) announced today that it was awarded a five-year, single-award, task order valued at up to $420 million to support the U.S. Army Combat Capabilities Development Command (DEVCOM), Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance & Reconnaissance (C5ISR) Center, and the Engineering and Systems Integration (ESI) Directorate.
  • The Replication, Exploitation, and Analysis of Commercial Threats (REACT) task order was awarded under the Responsive Strategic Sourcing for Services (RS3) indefinite delivery, indefinite quantity (IDIQ) contract vehicle.
  • “As complex, global system threats across all domains continue to escalate, CACI remains the Army’s trusted provider to continue its long-standing relationship protecting our warfighters from our adversaries,” said John Mengucci , CACI President and Chief Executive Officer.
  • “We are honored to deliver innovative expertise to combat these ever-evolving, advanced threats and support our customers in enabling and accelerating critical, mission-specific information and solutions.”
    For this contract, CACI provides engineering support, including mechanical, electrical, and modeling and simulation, to counter growing multi- and cross-domain threats at a rapid-fire pace to protect U.S. forces around the world from commercial threats that are no longer just in the aerial domain, but also ground, subterranean, sea, and undersea domains.

EverGlade Consulting Funding Alert: Advanced Research Projects Agency (ARPA-H) Solicits Proposals for Resilient Extended Automatic Cell Therapies (REACT) Program

Retrieved on: 
Wednesday, November 1, 2023
Sentinel, Advanced Research Projects Agency for Health, MAI, TAS, ARPA, Therapy, Biomarker, DARPA, Federation, BARDA, ASPR, Multimedia, Management consulting, DTRA, Public sector, ARPA-H, REACT, 2021 Giro d'Italia, Stage 1 to Stage 11, TA, NIH, Self-management, Patient, Technical area, Risk management, Pharmaceutical industry

CHARLESTON, S.C., Nov. 1, 2023 /PRNewswire/ -- The Advanced Research Projects Agency for-Health (ARPA-H) is actively seeking innovative proposals through the Resilient Extended Automatic Cell Therapies (REACT) program, employing a Master Announcement Instruction (MAI) strategy for proposal submissions. This strategy enables proposers to tailor their submissions according to the scale of their planned projects, categorized into small (BIT/BYTE), medium (KILO/MEGA), and large (GIG/TERA) scales. The REACT program specifically targets the large-scale GIG Module category, aiming to revolutionize therapeutic development and affordability, and enhance patient self-management. The program addresses the issue of ineffective therapeutics, often resulting not from medical unsoundness, but from patient barriers such as limited access and high costs, leading to compromised treatment adherence and poor health outcomes.

Key Points: 
  • By Laura Powell, Managing Consultant and Eric Jia-Sobota, Founder
    CHARLESTON, S.C., Nov. 1, 2023 /PRNewswire/ -- The Advanced Research Projects Agency for-Health (ARPA-H) is actively seeking innovative proposals through the Resilient Extended Automatic Cell Therapies (REACT) program, employing a Master Announcement Instruction (MAI) strategy for proposal submissions.
  • The REACT program specifically targets the large-scale GIG Module category, aiming to revolutionize therapeutic development and affordability, and enhance patient self-management.
  • Living Pharmacy track proposals must address TAs 1-4, and Living Sentinel track proposals must address TAs 1-3 and 5.
  • For additional information about EverGlade Consulting, visit: https://www.EverGlade.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/everglade-consulting-funding-al...

Leading Global CX Provider to Create Hundreds of Jobs with EMEA Expansion into Łódź, Poland

Retrieved on: 
Thursday, September 21, 2023
Software, Professional Services, Search Engine Optimization, Search Engine Marketing, Blogging, Data Management, Technology, Digital Marketing, Marketing, Advertising, Content Marketing, Communications, Consulting, Social responsibility, Inc., Partnership, Collaboration, REACT, CX, Woman, Acquisition, Economic development, BPO, Transport, Theretra alorica

Earlier this year, Alorica announced its expansion in EMEA , with launches in Poland and Egypt, in addition to its existing operations in Sofia, Bulgaria.

Key Points: 
  • Earlier this year, Alorica announced its expansion in EMEA , with launches in Poland and Egypt, in addition to its existing operations in Sofia, Bulgaria.
  • This investment targets high-growth markets with scalable talent, leveraging innovative technologies to engage employees and customers through work-at-home and onsite programs.
  • The company’s experienced team offers CX design, deployment and operations in over 30 languages, to leading companies across a range of in-demand industries.
  • Matt Sims, President of EMEA Operations at Alorica, emphasized the benefits that the new office brings to businesses seeking global expansion.

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Injection, Insurance, Duke Energy, Kidney failure, Chronic kidney disease, European Renal Association, Clinical trial, REACT, SGLT2, Dialysis, ERA, Congress, Patient, Kidney, Biostatistics, Research, CKD, Safety, D, Pharmaceutical industry, EU

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  • Around the end of 2023, we are also planning to report on the progress of participants in our open-label Phase 2 REGEN-007 study of REACT.
  • That study is designed to elicit visibility into the potential kidney outcomes of our commercial stage REACT formulation when injected into both kidneys.
  • ProKidney expects to commence enrollment in the second half of 2023 with initial interim data expected by the end of 2025.

Konica Minolta Awarded Platinum Honors from Campus Security & Life Safety

Retrieved on: 
Tuesday, July 18, 2023
Weapon, Partnership, Violence, Senior, Newsfirst Platinum Awards, REACT, Security, Organization, School, Student, Konica Minolta, Digital transformation, Mobile phone, Columbine

Ramsey, NJ, July 18, 2023 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. ( Konica Minolta ), today announced it received the Platinum Award in the Screening Equipment category of the 2023 Secure Campus Awards for its REACT - Visible Weapon Detection (School Security Solution).

Key Points: 
  • Ramsey, NJ, July 18, 2023 (GLOBE NEWSWIRE) -- Konica Minolta Business Solutions U.S.A., Inc. ( Konica Minolta ), today announced it received the Platinum Award in the Screening Equipment category of the 2023 Secure Campus Awards for its REACT - Visible Weapon Detection (School Security Solution).
  • The Secure Campus Awards, presented by Campus Security & Life Safety, honor the outstanding achievements of security industry manufacturers whose products and services are considered particularly noteworthy in their ability to improve campus security.
  • According to the Washington Post School Shootings Database , there have been 380 school shootings since 1999 (data as of May 1, 2023).
  • “We are particularly proud of this recognition from Campus Life & Security,” stated Vijay Raghavan, Senior Vice President, Digital Transformation and Emerging Businesses, Konica Minolta.

ProKidney Announces Purchase of Manufacturing Facility in Greensboro, NC

Retrieved on: 
Tuesday, June 13, 2023
Chronic kidney disease, Clinical trial, REACT, Food and Drug Administration, Biology, Patient, Investment, CKD, Food, Pharmaceutical industry, Cryptocurrency

Under the purchase agreement, ProKidney will pay approximately $25.5 million in cash for the facility and property.

Key Points: 
  • Under the purchase agreement, ProKidney will pay approximately $25.5 million in cash for the facility and property.
  • The transaction is expected to close by the end of June 2023, subject to customary closing conditions.
  • The Company plans to make investments in the facility through 2028 to prepare for potential commercial-scale manufacturing.
  • “This purchase represents an important component of our strategic manufacturing buildout,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney.